jane-kelly-shutterstock-com
JANE KELLY / SHUTTERSTOCK.COM
2 June 2016PharmaJane Wainwright and Tom Harding

In or out? How UK and European politics are shaking IP all about

Political issues around the world have long played a major role in shaping all areas of law and science, and neither intellectual property nor the life sciences have been immune to this. There is currently, however, a heightened level of political influence on IP in Europe and in particular the UK. Significant political battles are being fought in relation to UK membership of the EU and the unitary patent system, as well as more minor lobbying in other areas such as supplementary protection certificates (SPCs).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
15 October 2026   A dispute over missing experimental data and patent disclosures draws to a close as Boehringer and Dr Reddy’s deliver their final arguments. The court’s decision could bring greater clarity to the UK approach to plausibility and determine whether Dr Reddy’s can move ahead with its proposed generic launch.
Pharma
14 October 2026   Efforts to bring a generic cyanide poisoning treatment to market have suffered a setback after a US judge rejected challenges to three patents and criticised the drugmaker’s interpretation of the treatment’s chemical composition.
Pharma
13 October 2026   Generic challengers have scored a win against the Danish company after an appeals board revoked a key patent covering the cardiovascular use of semaglutide. The decision strips away another layer of protection as generic manufacturers hunt down the semaglutide franchise.